End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
323 TWD | -1.82% | +3.19% | +18.75% |
Sales 2024 * | 18.82B 581M 46.37B | Sales 2025 * | 21.2B 655M 52.24B | Capitalization | 83.84B 2.59B 207B |
---|---|---|---|---|---|
Net income 2024 * | 4.84B 150M 11.94B | Net income 2025 * | 6.2B 192M 15.28B | EV / Sales 2024 * | 4.76 x |
Net Debt 2024 * | 5.71B 176M 14.08B | Net Debt 2025 * | 1.56B 48.27M 3.85B | EV / Sales 2025 * | 4.03 x |
P/E ratio 2024 * |
17.5
x | P/E ratio 2025 * |
14.3
x | Employees | 1,099 |
Yield 2024 * |
1.66% | Yield 2025 * |
2.32% | Free-Float | 48.47% |
Latest transcript on Lotus Pharmaceutical Co., Ltd.
1 day | -1.82% | ||
1 week | +3.19% | ||
Current month | +6.25% | ||
1 month | +6.25% | ||
3 months | +16.61% | ||
6 months | +27.17% | ||
Current year | +18.75% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 28/09/14 | |
I ling Tian
DFI | Director of Finance/CFO | - | 31/10/16 |
Ying Ming Yue
COO | Chief Operating Officer | - | 30/11/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 60 | 10/08/14 | |
Director/Board Member | 61 | 22/04/15 | |
Han Fei Lin
BRD | Director/Board Member | - | 26/06/16 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 4 M€ | -4.41% | - | |
0.01% | 117 M€ | +0.79% | - | |
0.00% | 34 M€ | +1.99% | - | |
0.00% | 7 M€ | +0.11% | - |
Date | Price | Change | Volume |
---|---|---|---|
02/05/24 | 317 | -1.86% | 3,441,023 |
30/04/24 | 323 | -1.82% | 3,478,631 |
29/04/24 | 329 | +4.61% | 5,467,526 |
26/04/24 | 314.5 | +0.80% | 3,089,031 |
25/04/24 | 312 | -2.65% | 4,600,753 |
End-of-day quote Taiwan S.E., April 29, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.75% | 2.62B | |
+29.86% | 699B | |
+25.07% | 571B | |
-4.52% | 364B | |
+18.23% | 326B | |
+3.15% | 286B | |
+14.68% | 236B | |
+4.71% | 198B | |
-12.43% | 194B | |
-3.64% | 154B |
- Stock Market
- Equities
- 1795 Stock